These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 18993056

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients.
    Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A.
    Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759
    [Abstract] [Full Text] [Related]

  • 4. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
    Di Leo A, Gancberg D, Larsimont D, Tanner M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, Piccart MJ.
    Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
    [Abstract] [Full Text] [Related]

  • 5. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
    Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z, Shao Z, Lu J.
    Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Predicting anthracycline benefit: have we made any progress?
    Moretti E, Oakman C, Di Leo A.
    Curr Opin Oncol; 2009 Nov; 21(6):507-15. PubMed ID: 19713842
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New understanding of the role of anthracyclines in early-stage breast cancer: patient selection considerations.
    Gennari A, Pronzato P.
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S179-83. PubMed ID: 19158039
    [Abstract] [Full Text] [Related]

  • 10. Topoisomerase 2 alpha and the case for individualized breast cancer therapy.
    Glynn RW, Miller N, Whelan MC, Kerin MJ.
    Ann Surg Oncol; 2010 May; 17(5):1392-7. PubMed ID: 20217261
    [Abstract] [Full Text] [Related]

  • 11. Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer.
    O'Connor JK, Hazard LJ, Avent JM, Lee RJ, Fischbach J, Gaffney DK.
    Int J Radiat Oncol Biol Phys; 2006 Aug 01; 65(5):1411-5. PubMed ID: 16750309
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The topoisomerase II alpha gene status in primary breast cancer is a predictive marker of the response to anthracycline-based neoadjuvant chemotherapy.
    Kawachi K, Sasaki T, Murakami A, Ishikawa T, Kito A, Ota I, Shimizu D, Nozawa A, Nagashima Y, Machinami R, Aoki I.
    Pathol Res Pract; 2010 Mar 15; 206(3):156-62. PubMed ID: 20089371
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anthracycline war: no victor yet.
    Young P.
    J Natl Cancer Inst; 2009 Sep 02; 101(17):1171-3. PubMed ID: 19706625
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
    Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.
    Acta Oncol; 2006 Sep 02; 45(5):590-6. PubMed ID: 16864174
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
    Zhou Z, Guan H, Kleinerman ES.
    Mol Cancer Res; 2005 May 02; 3(5):271-5. PubMed ID: 15886298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.